3-胺基取代苯并吡喃酮类化合物的设计合成及抗肿瘤活性

根据生物电子等排原理, 设计并合成了一系列新颖的3-胺基取代苯并吡喃酮类化合物. 通过1H NMR, 13C NMR, MS, IR及元素分析确定其结构. 抗肿瘤活性测试结果表明, 部分该系列化合物对人结肠癌细胞株HCT116和人肝癌细胞株7721具有较好的抑制活性, 其中化合物6c, 6f, 6i, 6m和6o对人肝癌细胞株7721的半数抑制浓度(IC50)值均小于对照品姜黄素(IC50＝10.53 μmol•L－1), 化合物6f对人结肠癌细胞株HCT116和人肝癌细胞株7721的IC50值分别为5.57和4.92 μmol•L－1, 均小于姜黄素的相应值.     

Synthesis and Crystal Structure of (Z)-Ethyl-4-(4-methoxy)benzylidene-2-(3,5-dimethoxypheny-tetrahydrofuran-3,3-dicarboxylate

The title compound (Z)-ethyl-4-(4-methoxy)benzylidene-2-(3,5-dimethoxyphenyl)- tetrahydrofuran-3,3-dicarboxylate has been synthesized, and its crystal structure was characterized by X-ray single-crystal diffraction. The crystal belongs to triclinic, space group P1-, with a = 8.140(3), b = 11.966(4), c = 13.771(5) α = 67.366(4), β = 85.165(5), γ = 75.806(4)°, V = 1200.1(7) 3, Z = 2, C26H30O8, Mr = 470.50, Dc = 1.302 g/cm3, F(000) = 500, λ(MoKα) = 0.71073 , μ = 0.096 mm–1, R = 0.0659 and wR = 0.1841 for 3080 observed reflections (I > 2σ(I)). As a key intermediate of HIV-1 integrase inhibitor, the synthesis and structure confirmation of the title compound are important for further studies.